Literature DB >> 29076762

Surgical site infection after transoral versus posterior approach for atlantoaxial fusion: a matched-cohort study.

Mohamed Macki1, Azam Basheer1, Ian Lee1, Ryan Kather2, Ilan Rubinfeld2, Muwaffak M Abdulhak1.   

Abstract

OBJECTIVE In the past, spine surgeons have avoided the transoral approach to the atlantoaxial segment because of concerns for unacceptable patient morbidity. The objective of this study was to measure 30-day postoperative complications, especially surgical site infection (SSI), after transoral versus posterior approach to atlantoaxial fusion. METHODS The source population was provided by the American College of Surgeons National Surgical Quality Improvement Program database, which was queried for all patients who underwent atlantoaxial fusion for degenerative/spondylotic disease and/or trauma between 2005 and 2014. To eliminate bias from unequal sample sizes, patients who underwent the transoral approach were matched with patients who underwent the posterior approach (generally 1:5 ratio) based on age ± 5 years and modified frailty index score (a measure of preoperative comorbidity burden). Because of rare SSI incidence, adjusted odds ratios (ORadj) of SSI were calculated using penalized maximum likelihood estimation. RESULTS A total of 318 patients were included in the study. There were no statistically significant differences between the transoral cohort (n = 56) and the posterior cohort (n = 262) in terms of 30-day postoperative individual complications, including SSI (1.79% vs 1.91%; p = 0.951) and composite complications (10.71% vs 6.87%; p = 0.323). Controlling for sex and smoking, the odds of SSI in the transoral approach were almost equal to the odds in the posterior approach (ORadj 1.17; p = 0.866). While the unplanned reoperation rate of 5.36% after transoral surgery was higher than the 1.53% rate after posterior surgery, the difference approached, but did not reach, statistical significance (p = 0.076). CONCLUSIONS Transoral versus posterior surgery for atlantoaxial fusion did not differ in 30-day unexpected outcomes. Therefore, spinal pathology, rather than concern for postoperative complications, should adjudicate the technical approach to the atlantoaxial segment.

Entities:  

Keywords:  ACS = American College of Surgeons; AIC = Akaike information criterion; C-1; C-2; CPT = Current Procedural Terminology; NSQIP = National Surgical Quality Improvement Program; ORadj = adjusted odds ratio; ORunadj = unadjusted odds ratio; SSI = surgical site infection; atlantoaxial; cervical; mFI = modified frailty index; surgical site infection; transoral

Mesh:

Year:  2017        PMID: 29076762     DOI: 10.3171/2017.5.SPINE161064

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  4 in total

1.  Incidence and management of surgical site infection in the cervical spine following a transoral approach.

Authors:  Hu Chen; Changrong Zhu; Honglei Yi; Hao Sun; Xiangyang Ma; Jianhua Wang; Kai Zhang; Fuzhi Ai; Zenghui Wu; Qingshui Yin; Qiang Tu; Hong Xia
Journal:  Int Orthop       Date:  2022-06-30       Impact factor: 3.479

2.  Research on pharyngeal bacterial flora in transoral atlantoaxial operation and the postoperative follow-up study.

Authors:  Yu Zhang; Suo-Chao Fu; You Wu; Chu-Song Zhou; Xiang-Yang Ma
Journal:  BMC Musculoskelet Disord       Date:  2022-10-19       Impact factor: 2.562

3.  Individualized perioperative management in transoral spine surgery: a single-center cohort study evaluating surgical wound complications and wound infections.

Authors:  Vera Spatenkova; David Sila; Milada Halacova; Jan Hradil; Zdenek Krejzar; Eduard Kuriscak
Journal:  BMC Anesthesiol       Date:  2022-04-27       Impact factor: 2.376

4.  The influence of sagittal spinopelvic alignment on patient discharge disposition following minimally invasive lumbar interbody fusion.

Authors:  Mohamed Macki; Hassan A Fadel; Travis Hamilton; Seokchun Lim; Lara W Massie; Hesham Mostafa Zakaria; Jacob Pawloski; Victor Chang
Journal:  J Spine Surg       Date:  2021-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.